Immediate suspension of manufacturing licences on NSQ findings marks a shift from a procedure-first to a safety-first drug regulatory regime. Critically examine its implications for due process and public health.

The draft amendments to the Drugs Rules, 1945 allow a manufacturing licence to be suspended as soon as a Government Analyst declares a drug Not of Standard Quality (NSQ) on five critical parameters: assay, dissolution, related substances, impurities and sterility. At present, a show-cause notice must come first [1]. The change protects patients but gives up some due process, and careful design can limit that cost.

Public health: gains

• Shorter exposure window: substandard batches no longer stay on sale while show-cause paperwork moves [1].
• Proportionate trigger: only failures that can harm patients count, such as sterility failures in injectables or under-dosing shown by assay and dissolution tests. Labelling lapses do not [1].
• Wider harms curbed: WHO links substandard products to treatment failure, toxicity and antimicrobial resistance [6].
• Federal coordination: the amended Form 13 sends the report to the DCGI, the licensing authority of the State where the drug is made, and the marketer [1].

Due process: concerns

• Action before hearing: the right to be heard (audi alteram partem) is postponed until after the penalty.
• Retest bypassed: under Section 25, D&C Act, 1940, a manufacturer can contest the analyst's report, and the Central Drugs Laboratory's (CDL) finding is conclusive [2]. Suspension now comes before that retest.
• Fallible trigger: a Parliamentary Standing Committee flagged weak government labs, non-validated test methods and staff shortages [3].
• Open-ended suspension: lifting it needs a verified Root Cause Analysis and corrective plan (RCA/CAPA), but no deadline is set for verification [1].
• Capacity strain: States/UTs tested 1,16,323 samples in 2024-25, and about 2.7% were NSQ [4]. With Drugs Controller posts persistently vacant [5], re-inspections may lag. MSMEs would suffer most.
• Rules vs Act: a "suspend first" norm set by executive rules can be challenged in court as going beyond the parent Act.

Way forward

• Set fixed deadlines for the CDL retest and for RCA/CAPA verification.
• Fill vacancies and empanel more testing labs, as the Standing Committee recommends [5].
• Write the power into the new drugs law, and pair it with revised Schedule M for prevention at the factory.

Overall, the rule rightly puts the right to health under Article 21 ahead of commercial continuity. Its evidence-based trigger and conditional revocation also limit arbitrary use. With fixed timelines and stronger labs, the regime can be both safety-first and fair, advancing SDG 3.8 (access to quality medicines) and India's credibility as the "pharmacy of the world".